+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID07646613

Randomized, Double-Blind Crossover Trial Evaluating ASY202 Inhalation Powder Versus Placebo for Acute Migraine Treatment in Adults

Led by Aspeya, Inc. · Updated on 2026-10-09

108

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the investigational inhaled migraine medication ASY202 to assess its effectiveness, safety, and tolerability in adults with migraine. This Phase 2 clinical trial uses a randomized, double-blind, placebo-controlled, crossover design, involving adults aged 18 to 65 with a history of migraine. Participants will receive both ASY202 and placebo at different times during the study, without knowing which treatment they are receiving. The study is sponsored by Aspeya, Inc. and aims to better understand how ASY202 works for acute migraine treatment. Participants will use a handheld dry powder inhaler to take ASY202, a pre-metered dry powder formulation of dihydroergotamine DHE, during migraine attacks. The study includes two treatment periods separated by a washout period of at least 7 days. In Treatment Period 1, one group will receive ASY202 followed by placebo in Treatment Period 2, while the other group receives placebo first then ASY202. The placebo is an inactive inhalation powder delivered with a matching inhaler device. During the approximately 16-week study, participants will undergo screening, two treatment periods, and a safety follow-up visit. Researchers will monitor headache pain relief and freedom from pain at various timepoints post-dose, including 2 hours and up to 48 hours, as well as the use of rescue medication and functional ability. Safety assessments will track adverse events from screening through study completion. The study includes multiple visits to evaluate efficacy and tolerability throughout the trial.

CONDITIONS

Brief Title

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

Research Team

E

Eken

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here